Komori
JCR Pharmaceuticals (4552) · RiskPolicy for recovering upfront payments and stabilizing the earnings structure

Risk of relying on contract-fee income for growth investment

First written in FY2025. 1 of 2 entries say "Materialised", first in FY2025. Latest entry: FY2026.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY20252025: 120252026: 12026
Same theme, other companies
Revenue Dependence on Partnership Income and Development MilestonesA theme 7 companies write about · 7 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 3 of 6 companies on the "Worse" side.

1 other company's latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of relying on contract-fee income for growth investment | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori